News and Updates

AstraZeneca’s latest clinical setback forces investors to rethink pharma valuation. Learn how R&D risks and pipeline diversity shape long-term stock value.

A new Phase 2 trial shows a promising Shigella vaccine induces a strong immune response, potentially offering a breakthrough against antibiotic-resistant bacteria.

Amgen is defending its vasculitis drug Tavneos amid global regulatory concerns over safety. Learn about the potential impact on clinical guidelines.

A world-first study confirms a breakthrough procedure safely treats Twin-to-Twin Transfusion Syndrome, offering new hope for high-risk twin pregnancies.

Innovative trial designs are set to accelerate early-stage CAR-T cancer research, improving safety protocols and speeding up the delivery of new therapies.

Humanoid robots have successfully performed their first live gallbladder surgeries. Discover how this medical breakthrough is reshaping robotic surgery.

The FDA has cleared Fate Therapeutics’ FT839 for clinical trials. Discover how this off-the-shelf CAR-T therapy aims to revolutionize autoimmune treatment.

Discover three psychedelic medicine companies nearing critical clinical trial data that could reshape mental health treatment and attract investor interest.

AstraZeneca’s Wainua fails to meet primary endpoints in the CARDIO-TTRansform heart disease trial, prompting expert scrutiny over study design and efficacy.

New Phase 2 trial results for tralokinumab show promising safety and pharmacokinetics for children suffering from moderate-to-severe atopic dermatitis.